BPC-157 human IV safety pilot
PubMed
TL;DR
A tiny two-person pilot found that IV BPC-157 at 10 mg and 20 mg was tolerated without measured short-term laboratory abnormalities, but it cannot establish general human safety or efficacy.
Human safety pilot · 2 participants
What was studied
The question.
Whether intravenous BPC-157 produced immediate safety problems or measurable laboratory changes in humans.
How it was conducted
The study design.
Two adults at a private Florida clinic received 10 mg IV BPC-157 on day one and 20 mg on day two, each infused over one hour. Vital signs and fasting laboratory markers were checked before and after treatment, and participants were asked about side effects.
What it found
Did it actually work?
- No adverse effects were reported by either participant.
- The investigators reported no measurable adverse changes in the tested heart, liver, kidney, thyroid or glucose markers.
Why it matters
How to read this result.
Human BPC-157 data are exceptionally sparse, so even a very small exposure study is useful context. It shows that human exposure has been formally documented rather than the evidence being exclusively animal-based.
Keep in mind
What the study does not prove.
- Only two people participated.
- Both participants had previously received IV BPC-157.
- There was no placebo group and no efficacy outcome.
- The study cannot establish uncommon, delayed or long-term risks.
Original source
Want to read the original?
We summarize the study here first. The original source is there when you want the full methods, statistics, tables and author discussion.
Open study record